The overall goals ofthe Administrative Core are to provide leadership and the organizational backbone for this proposal, promote collaboration between the projects and cores, and coordinate interactions with external entities such as the National Heart, Lung, and Blood Institute (NHLBI) and the Food and Drug Administration (FDA). To accomplish these goals, we propose specific tasks listed below. Specific Task 1: To facilitate communication among Projects 1-3 and Cores A and B and to assist all projects in manuscript preparation and submission as well as assist scientists in registering manuscripts on PubMed Central. Specific Task 2: To provide mechanisms for communication between the University of Wisconsin, NHLBI, and internal and external project reviewers. Specific Task 3: To provide regulatory support to all projects and cores through interactions with the University of Wisconsin Health Sciences Institution Review Board (IRB) and the FDA. The Administrative Core will interact with all projects and cores in this proposal through organization, notification, and distribution of meeting minutes of monthly internal project review meetings. The Administrative Core will oversee the rate of subject accrual to ensure that each project is able to meet its required sample size. The core will be responsible for preparation and submission of annual progress reports to the Institute and will organize external and internal reviews as needed. Finally, the core will work with the FDA with regard to an Investigational New Drug (IND) application for the proposed use of segmental bronchoprovocation with allergen using house dust mite, cat, or ragweed allergen.
The overall objective of this core is to provide administrative support for the entire program project grant. By providing this support, each project and remaining core can focus on completing research for their proposed scientific questions to meet the overall goal of this grant.
|Esnault, S; Johansson, M W; Kelly, E A et al. (2017) IL-3 up-regulates and activates human eosinophil CD32 and ?M?2 integrin causing degranulation. Clin Exp Allergy 47:488-498|
|Rajaram, Satwik; Heinrich, Louise E; Gordan, John D et al. (2017) Sampling strategies to capture single-cell heterogeneity. Nat Methods 14:967-970|
|Mosher, Deane F; Wilkerson, Emily M; Turton, Keren B et al. (2017) Proteomics of Eosinophil Activation. Front Med (Lausanne) 4:159|
|Liu, Y-P; Rajamanikham, V; Baron, M et al. (2017) Association of ORMDL3 with rhinovirus-induced endoplasmic reticulum stress and type I Interferon responses in human leucocytes. Clin Exp Allergy 47:371-382|
|Esnault, Stephane; Torr, Elizabeth E; Bernau, Ksenija et al. (2017) Endogenous Semaphorin-7A Impedes Human Lung Fibroblast Differentiation. PLoS One 12:e0170207|
|Esnault, Stephane (2017) The neglected of eosinophil biology, IL-3 finds sustenance in the basophil. J Leukoc Biol 101:615-616|
|Esnault, Stephane; Bernau, Ksenija; Torr, Elizabeth E et al. (2017) RNA-sequencing analysis of lung primary fibroblast response to eosinophil-degranulation products predicts downstream effects on inflammation, tissue remodeling and lipid metabolism. Respir Res 18:188|
|Shen, Zhong-Jian; Hu, Jie; Kashi, Venkatesh P et al. (2017) Epstein-Barr Virus-induced Gene 2 Mediates Allergen-induced Leukocyte Migration into Airways. Am J Respir Crit Care Med 195:1576-1585|
|Johansson, M W; Khanna, M; Bortnov, V et al. (2017) IL-5-stimulated eosinophils adherent to periostin undergo stereotypic morphological changes and ADAM8-dependent migration. Clin Exp Allergy 47:1263-1274|
|Kelly, Elizabeth A; Esnault, Stephane; Liu, Lin Ying et al. (2017) Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma. Am J Respir Crit Care Med 196:1385-1395|
Showing the most recent 10 out of 95 publications